Cargando…
Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial)
BACKGROUND: The POP Trial was a phase 1, open-label, rising-dose, randomised study that explored the safety and tolerability of calmangafodipir (superoxide dismutase mimetic) co-treatment with n-acetylcysteine (NAC) for paracetamol overdose. METHODS: Patients were recruited at the Royal Infirmary of...
Autores principales: | Morrison, Emma E., Oatey, Katherine, Gallagher, Bernadette, Grahamslaw, Julia, O'Brien, Rachel, Black, Polly, Oosthuyzen, Wilna, Lee, Robert J., Weir, Christopher J., Henriksen, Dennis, Dear, James W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710902/ https://www.ncbi.nlm.nih.gov/pubmed/31311721 http://dx.doi.org/10.1016/j.ebiom.2019.07.013 |
Ejemplares similares
-
Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol overdose—the PP100–01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial
por: Dear, James
Publicado: (2019) -
Letter in response to: “Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose—the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial”
por: Karlsson, Jan Olof G., et al.
Publicado: (2019) -
Gastrointestinal AEs seen in the POP trial due to SOD mimetic activity of calmangafodipir? – Authors' reply
por: Dear, James W.
Publicado: (2019) -
Safety and Efficacy of the SNAP 12-hour Acetylcysteine Regimen for the Treatment of Paracetamol Overdose
por: Pettie, Janice M., et al.
Publicado: (2019) -
Gastrointestinal AEs seen in the POP trial due to SOD mimetic activity of calmangafodipir?
por: Karlsson, Jan Olof G.
Publicado: (2019)